Synergistic effects of sulopenem in combination with cefuroxime or durlobactam against Mycobacterium abscessus.

ABSTRACT: Mycobacterium abscessus (Mab) affects patients with immunosuppression or underlying structural lung diseases such as cystic fibrosis (CF). Additionally, Mab poses clinical challenges due to its resistance to multiple antibiotics. Herein, we investigated the synergistic effect of dual β-lactams [sulopenem and cefuroxime (CXM)] or the combination of sulopenem and CXM with β-lactamase inhibitors [BLIs-avibactam (AVI) or durlobactam (DUR)]. The sulopenem-CXM combination yielded low minimum inhibitory concentration (MIC) values for 54 clinical Mab isolates and ATCC19977 (MIC₅₀ and MIC₉₀ ≤0.25 µg/mL). Similar synergistic effects were observed in time-kill studies conducted at concentrations achievable in clinical settings. Sulopenem-CXM outperfor

SUBMITTER: Dousa KM 

PROVIDER: S-EPMC11237399 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature